Attention-deficit/hyperactivity disorder drugs and growth: An Italian prospective observational study

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 7, 2013, Pages 440-447

  Germinario, Elena A P ^a   Arcieri, Romano ^a   Bonati, Maurizio ^b   Zuddas, Alessandro ^c   Masi, Gabriele ^d   Vella, Stefano ^a   Chiarotti, Flavia ^a   Panei, Pietro ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d DEPARTMENT OF DEVELOPMENTAL NEUROSCIENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE;

ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BODY HEIGHT; BODY WEIGHT; CHILD; CHILD GROWTH; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONDUCT DISORDER; CONTROLLED STUDY; DEPRESSION; DRUG DOSE INCREASE; DRUG MARKETING; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GROWTH ACCELERATION; HUMAN; LEARNING DISORDER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPPOSITIONAL DEFIANT DISORDER; PHASE 4 CLINICAL TRIAL; PRESCHOOL CHILD; PRESCRIPTION; PROSPECTIVE STUDY; SAMPLE SIZE; SCHOOL CHILD; SEX RATIO; STRUCTURED INTERVIEW; TREATMENT DURATION; WEIGHT GAIN;

ADOLESCENT; ADOLESCENT DEVELOPMENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BODY HEIGHT; BODY WEIGHT; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD DEVELOPMENT; FEMALE; HUMANS; ITALY; MALE; METHYLPHENIDATE; PROPYLAMINES; PROSPECTIVE STUDIES; REGISTRIES;

EID: 84884507817     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2012.0086     Document Type: Article

References (20)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994 Biederman J, Faraone SV: Attention-deficit hyperactivity disorder. Lancet 366:237-248, 2005.
2. Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R: Stimulant treatment over 5 years: Effect on growth. J Am Acad Child Adolesc Psychiatry 45:415-421, 2006.
3. Cheng JY, Chen RY, Ko JS, Ng EM: Efficacy and safety of Atomoxetine for attention-deficit hyperactivity disorder in children and adolescents-meta- analysis and meta-regression analysis. Psychopharmacology 194:197-209, 2007.
4. Cohen I: Statistical Power Analysis for the Behavioural Sciences, Hilsdale, NI: Lawrence Erlbaum Associates Inc., 1988.
5. Donnelly C, Bangs M, Trzepacz P, Jin L, Zhang S, Witte MM, Ball SG, Spencer TJ: Safety and tolerability of Atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 48:176-185, 2009.
6. Faraone SV, Biederman J, Morley CP, Spencer TJ: Effect of stimulants on height and weight: A review of the literature. J Am Acad Child Adolesc Psychiatry 47:994-1009, 2008.
7. Greenhill LL, Vitiello B, Riddle MA, Fisher P, Shockey E, March JS, Levine J, Fried J, Abikoff H, Zito JM, McCracken JT, Findling RL, Robinson J, Cooper TB, Davies M, Varipatis E, Labellarte MJ, Scahill L, Walkup JT, Capasso L, Rosengarten J: Review of safety assessment methods used in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 42:627-633, 2003.
8. Klein RG, Landa B, Mattes JA, Klein DF: Methylphenidate and growth in hyperactive children. A controlled withdrawal study. Arch Gen Psychiatry 45:1127-1130, 1988.
9. Klein RG, Mannuzza S: Hyperactive boy almost grown up. III. Methylphenidate effect on ultimate height. Arch Gen Psychiatry 45:1131-1134, 1988.
10. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, Gelowitz DL: Effect of long-term Atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:919-927, 2006.
11. Mattes JA, Gittelman R: Growth of hyperactive children on maintenance regimen of Methylphenidate. Arch Gen Psychiatry 40:317-321, 1983.
12. MTA Cooperative Group: A 14-month randomised clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1073-1086, 1999.
13. Panei P, Arcieri R, Vella S, Bonati M, Martini N, Zuddas A: Italian attention-deficit/hyperactivity disorder registry. Pediatrics 114:514, 2004.
14. Safer DJ, Allen RP, Barr E: Growth rebound after termination of stimulant drugs. J Pediatr 86:113-116, 1975.
15. Schachter HM, Pham B, King J, Langford S, Moher D: How efficacious and safe is short-acting Methylphenidate for treatment of attention-deficit disorder in children and adolescents? A metaanalysis. CMAJ 165:1475-1488, 2001.
16. Skounti M, Philalithis A, Galanakis E: Variations in prevalence of attention deficit hyperactivity disorder worldwide. Eur J Pediatr 166:117-123, 2007.
17. Spencer TJ, Newcorn JH, Kratochvil CJ, Ruff D, Michelson D, Biederman J: Effect of Atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics 116:e74-e80, 2005.
18. Takahashi M, Takita Y, Yamazaki K, Hayashi T, Ichikawa H, Kambayashi Y, Koeda T, Oki J, Saito K, Takeshita K, Allen AJ: A randomized, double-blind, placebo-controlled study of Atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 19:341-350, 2009.
19. Tanner JM, Whitehouse RH, Takaishi M: Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children 1965. Arch Dis Child 41:454-471, 1966.
20. Villarreal JM, Hernández-Lucas I, Gil F, Calderón IL, Calva E, Saavedra CP: A naturalistic 10-year prospective study of height and weight in children with attention deficit/hyperactivity disorder grown up: sex and treatment effects. J Pediatr 157:636-640, 2010.